Sai Life Science IPO Day 3 Live Updates: Key Highlights, Subscription Status, and Insights
Sai Life Sciences operates as an integrated CRDMO (Contract Research, Development, and Manufacturing Organization), providing end-to-end solutions in the drug discovery and development process. It has come up with an IPO. The subscription for the same is still on. Today, the 13th of December 2024, is Day 3 or the last day of the IPO applications
Sai Life Sciences IPO Details
- Sai Life Sciences IPO is a book built issue of Rs 3,042.62 crores. The issue is a combination of fresh issue of 1.73 crore shares aggregating to Rs 950.00 crores and offer for sale of 3.81 crore shares aggregating to Rs 2,092.62 crores.
- Sai Life Sciences IPO price band is set at ₹522 to ₹549 per share. The minimum lot size for an application is 27 Shares. The minimum amount of investment required by retail investors is ₹14,823. The minimum lot size investment for sNII is 14 lots (378 shares), amounting to ₹207,522, and for bNII, it is 68 lots (1,836 shares), amounting to ₹1,007,964.
- Sai Life Sciences IPO Day 3 Subscription Status
Sai Life Sciences IPO subscribed 3.60 times by December 13, 2024, 2:21:12 PM.
- The Non-Institutional Investors (NIIs) subscribed to 2.55 times their allotted quota.
- The Retail Investors segment received subscriptions of 0.74 times their allocation.
- The QIB category subscribed to 9.40 times their allotted quota.
Utilization of IPO Proceeds
The company proposes to utilise the Net Proceeds towards funding the following objects:
- Repayment/prepayment in full or part of all or certain outstanding borrowings availed by the Company and
- General corporate purposes
Shareholding Pre & Post Issue
|
Shareholding |
% |
|
Shareholding Pre Issue |
40.48 |
|
Shareholding Post Issue |
35.10 |
Sai Life Science Business Overview
Sai Life Sciences operates as an integrated CRDMO (Contract Research, Development, and Manufacturing Organization), providing end-to-end solutions in the drug discovery and development process. It competes with peers like Divi's Laboratories, Suven Pharmaceuticals, and Syngene International. The company serves leading global pharmaceutical firms and has a strong R&D infrastructure.
In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023. The services were offered across countries such as the US, the UK, Europe, and Japan.
Service Offerings:
- Capabilities in chemistry, manufacturing, and control(“CMC”)/contract development and manufacturing organisations (“CDMO”).
- CRO services include integrated discovery (“Discovery”) capabilities across biology, chemistry, drug metabolism and pharmacokinetics
Sai Life Science Financials
Sai Life Science Limited's revenue and profit after tax (PAT) have shown decent growth between the financial year ending March 31, 2024 and March 31, 2023.
- Revenues increased from 1245.11 Cr for the period ending March 2023 to 1494.27 Cr for the period ending March 2024, registering a healthy 20% growth.
- Profits have increased from 9.99 Cr in March 2023 to 82.81 Cr in March 2024, registering a spectacular growth of 729%.